Live
BioPharma DiveAvalyn, in pursuit of better lung drugs, banks $300M in an IPO10x Genomics NewsVanguard holds 6.17M shares of 10X Genomics (NASDAQ: TXG), 5.24% stake - Stock Titan10x Genomics Blog10x Genomics investors can watch management at a May 13 BofA chat - Stock Titan10x Genomics News10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - PR Newswire10x Genomics Blog10x Genomics to Participate in the BofA Securities 2026 Healthcare Conference - Yahoo Finance UKFierceBiotechFDA hits Newron’s phase 3 schizophrenia trial with clinical hold in US after patient deathEndpoints NewsAbbVie faces questions about Skyrizi competition from J&JEndpoints NewsFDA, AstraZeneca prep for oncology adcommAgilentPCR Plate Sealer Market Leading Players Analysis - Agilent - openPR.com10x Genomics NewsWhy 10x Genomics Stock Is Sinking Today - TipRanksLonza NewsLonza Capsugel donates $50,000 to Project Hope Foundation - Index-Journal
BioPharma Dive Apr 30, 2026

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Avalyn, in pursuit of better lung drugs, banks $300M in an IPO

Original
Body unavailable. Use the original source.